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Bronchoscopy · Emphysema · Endobronchial coils · Lung 
volume reduction
Abstract
Background: The PneumRx endobronchial coil system for 
patients with severe emphysema has been shown to im-
prove quality of life, exercise capacity, and pulmonary func-
tion in patients with emphysema. A post hoc analysis of the 
RENEW trial has identified patient characteristics and lobar 
selection methods associated with improved outcomes, 
which have to be confirmed prospectively. Methods: The 
ELEVATE trial is a prospective, multicenter, open label, ran-
domized (2: 1), controlled trial comparing outcomes in pa-
tients treated with endobronchial coils (treatment) to a med-
ically managed control group (control). The trial aims to en-
roll 210 patients (140 in the treatment group and 70 in the 
control group) with severe emphysema. Control patients will 
be eligible to crossover to coil treatment after 6 months of 
follow-up. The co-primary effectiveness endpoints are per-
cent change in forced expiratory volume in 1 s and quality of 
life measured by change in St. George’s Respiratory Ques-
tionnaire from baseline to 6 months. Secondary objectives 
are determination of responder rates of clinical endpoints 
and mean change in other functional and physiologic end-
points. All patients will be followed for 24 months after initial 
treatment. Adverse events will be collected on an ongoing 
basis throughout the trial. Discussion: The primary objective 
of the ELEVATE trial is to prospectively confirm the safety and 
effectiveness profile of the coil system for the treatment of 
severe emphysema in consideration of the findings of previ-
ous randomized controlled trials. Secondary objectives are 
the determination of responder rates in all clinical endpoints 
and mean change in physiologic endpoints.
© 2019 The Author(s) 
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The estimated global prevalence of emphysema is 1.8% 
[1]. Upon disease progression, patients with emphysema 
develop hyperinflation with an increase in residual vol-
ume (RV) and total lung capacity (TLC) caused by the 
gradual destruction of alveolar walls and loss of the lung’s 
natural elastic recoil which results in the collapse of un-
supported airways during exhalation. Eventually, pa-
tients develop hypoxemia and deconditioning that con-
tribute to muscle weakness and fatigue. The crippling ef-
fects of end-stage emphysema include severe dyspnea, 
severe limitation of activities, depression/anxiety, recur-
rent exacerbation, and ultimately respiratory failure, 
which may finally result in death [2].
There are limited treatment options for patients with 
severe emphysema that include medications, pulmonary 
rehabilitation, supplemental oxygen, and surgical proce-
dures (lung transplantation and lung volume reduction 
surgery [LVRS]) [2]. Since the NETT (National Emphy-
sema Treatment Trial) [3], which established the concept 
of LVRS, many clinical trials have demonstrated the effect 
of lung volume reduction leading to a significant im-
provement in lung function, exercise capacity, and qual-
ity of life (QoL) [4]. However, due to the increased risk of 
morbidity and mortality associated with thoracic surgery 
[4, 5], the lack of sufficient organ donors, and as not all 
patients are eligible for LVRS, there is an unmet need for 
minimally invasive therapies to reduce lung volume in 
hyperinflation. Recent years have seen the development 
of various techniques for endoscopic lung volume reduc-
tion [6], including endobronchial valves [7–9], coils [10], 
bronchoscopic thermoablation [11], and biological lung 
volume reduction with a sealant [12]. Post hoc analyses 
of VENT (Endobronchial Valve for Emphysema Pallia-
tion Trial) and subsequent prospective randomized stud-
ies identified complete occlusion of the treated lobe with 
absence of collateral ventilation to be a strong predictor 
of response to endobronchial valve therapy [8, 9, 13–18]. 
Collateral ventilation, however, is a common status in 
emphysema patients, with a prevalence of 50–90% de-
pending on the lung [19]. The high screening failure rates 
in clinical trials of valve therapy thus demonstrate a need 
for alternative, complementary treatment options: for ex-
ample, in the LIBERATE study [18], out of 909 patients 
that consented to participate in the study, 190 were fi-
nally randomized. Patients who are not candidates for 
valve therapy might be eligible for coil treatment. 
In the RENEW trial, participants were randomly as-
signed to receive either bilateral coil treatment involving 
2 sequential procedures in which 10–14 coils were bron-
choscopically placed in a single lobe of each lung or usu-
al care alone. The study demonstrated statistically signif-
icant improvements in exercise capacity and QoL in pa-
tients treated with endobronchial coils; however, 
improvements in exercise capacity in the intent-to-treat 
(ITT) population were considered modest and of uncer-
tain clinical importance [20, 21]. Recently, post hoc anal-
ysis of the RENEW trial established patient baseline char-
acteristics and lobe selection criteria that are associated 
with improved outcomes following endobronchial coil 
treatment [21]. Patients identified as responders in this 
post hoc analysis had higher emphysema scores (% low 
attenuation area [LAA] at –950 Hounsfield units [HU]), 
a baseline RV of at least 200% of predicted, and absence 
of significant airway disease in high-resolution computed 
tomography (HRCT), as identified by independent re-
viewers. In addition, quantitative computed tomography 
(QCT) analysis was shown to be important in determin-
ing the lobe with the greatest ipsilateral emphysema score, 
especially in patients with homogeneous emphysema [22, 



































■ Patients with volume reduction criteria (n = 50)
■ Patients without volume reduction criteria (n = 28)
Fig. 1. Responder rates in patients with and without identified pre-
dictive criteria for response. Volume reduction criteria were “no 
airway disease,” low attenuation area ≥20%, residual volume (RV) 
≥200% of predicted. Patients who met those criteria had signifi-
cantly higher response rates in clinical endpoints, using standard 
minimum clinical important differences: RV –350 mL, forced ex-
piratory volume in 1 s (FEV1) 10%, 6-min walking  test (6MWT) 
26 m, St. George’s Respiratory Questionnaire (SGRQ) –4 points. 
Both subgroups were treated in the most damaged lobes as mea-
sured by quantitative CT analysis. Reprinted from Slebos et al. [21] 





was associated with significant improvement in lobar vol-
ume reduction 12 months after coil treatment [21].
From the RENEW post hoc analysis, both visual and 
QCT methods as well as traditional baseline pulmonary 
function tests appear to be important to maximize re-
sponse to endobronchial coil treatment (Fig. 1). Based on 
these findings, the ELEVATE trial was designed to con-




The ELEVATE trial (ClinicalTrials registration No. 
NCT0336039) is a prospective, multicenter, open-label, random-
ized, controlled trial comparing outcomes in patients treated with 
endobronchial coils (treatment group) to a medically managed 
control group (control group). Since this is an open-label study, 
there will be no sham procedure in the control group. A total of 
210 patients will be randomized in a 2: 1 ratio of treatment to con-
trol, respectively (140 patients in the treatment group and 70 pa-
tients in the control group), in up to 30 sites across Europe (there 
are some regional protocol amendments based on authority re-
quirements regarding follow-up or radiation protection) with a 
minimum of 82 subjects determined to have bilaterally heteroge-
neous emphysema, defined as ≥15% difference in LAA at –950 HU 
between ipsilateral lobes analyzed by QCT software in both lungs, 
respectively (Tables 1, 2). All patients will be stratified by site and 
emphysema heterogeneity: each site will be allocated the same per-
centage of patients in the treatment or control arm, and also with 
heterogeneous or homogeneous emphysema. The process of eligi-
bility is described in detail below (see Screening Assessment). 
Once the patient fulfills all inclusion criteria and is accepted by the 
Eligibility Review Committee (ERC) (Fig. 3), the randomization, 
which is activated by the investigator, is automated and built into 
the electronic case report form. Randomization will be determined 
using assignment by a computer-generated randomization 
scheme.
All patients randomized to treatment will be followed for 24 
months after the initial treatment. Control group patients will be 
eligible for treatment with coils (crossover) 6 months after ran-
domization, at which point they will be evaluated for crossover. 
Crossover patients will then be followed for 24 months after coil 
treatment.
Screening Assessments
The study population will include patients with severe emphy-
sema indicated for coil treatment per the approved, CE-marked 
instructions for use who meet the inclusion/exclusion criteria 
(Tables 1, 2). A completed patient informed consent form will be 
required from all participating patients. The informed consent 
form will be reviewed and approved by the ethics committees of all 
participating sites. The study will be conducted in accordance with 
Good Clinical Practice guidelines, and all applicable country, state, 
and local regulations.
Assessing HRCT for Inclusion Criteria
In prior coil studies, the most damaged lobe was defined visu-
ally either by the physician or a core lab. In ELEVATE, QCT anal-
ysis will assess the degree of emphysematous lung tissue (LAA) in 
the HRCT. The threshold for this analysis is defined as <–950 HU. 
This analysis will be used to identify the most destroyed lobe in the 
right and left lungs, which will be the target lobes for treatment. 
BTG/PneumRx will provide sites with an anonymized lung densi-
tometry report that will identify lobar volumes and the degree of 
destruction (LAA) based on –950 HU for each lobe (Fig. 2).
In addition, all HRCT scans will be reviewed by an independent 
Radiology Review Committee (RRC) composed of expert radiolo-
gists who will perform a comprehensive assessment of the HRCT 
of features relevant for endobronchial coil therapy. The RRC will 
assess and describe the following morphological signs in the lung: 
emphysema distribution (centrilobular, panlobular, paraseptal), 
airway wall thickening, bronchiectasis, inflammatory small airway 
disease, mucous plugging, imaging consistent with active pulmo-
nary infection, significant interstitial or pleural disease, significant 
bullae, nodules or other lung pathologies, radiographic confirma-
tion of atelectasis, or other scarring/fibrosis in areas of intended 
coil implant.
The report from the RRC will be provided to the ERC who will 
approve the eligibility of each patient (Fig. 3). The ERC consists of 
5 experienced interventional pulmonologists who are experts in 
lung volume reduction procedures and patient selection [21]. This 
Table 1. The ELEVATE trial inclusion criteria
– Read, understood, and signed the informed consent form
– Meets indications for use per IFU
– Bilateral heterogeneous and/or homogeneous emphysema
– 15% predicted ≤ FEV1 after bronchodilation ≤ 45% predicted
– RV after bronchodilation ≥200% predicted
– TLC after bronchodilation >100% predicted
– RV/TLC after bronchodilation >55%
– Dyspnea ≥2 on mMRC dyspnea scale despite optimal  
medical management
– Receiving optimal drug therapy and medical management 
according to clinical practice
– Performing regular physical activity at least twice/week
– Stopped smoking as confirmed by CoHb 
– 100 m ≤ 6MWT ≤ 450 m
– Deemed eligible per ERC 
The World Health Organization defines physical activity as any 
bodily movement produced by skeletal muscles that requires en-
ergy expenditure – including activities undertaken while working, 
playing, carrying out household chores, traveling, and engaging in 
recreational pursuits. For those with limited mobility, this should 
be done at least 2 days per week. There was no specific duration of 
smoking cessation required in the protocol, but those with a CoHb 
level <2.5% were defined as nonsmokers. 6MWT, 6-min walking 
test; CoHb, carboxyhemoglobin; ERC, Eligibility Review Commit-
tee; FEV1, forced expiratory volume in 1 s; IFU, instructions for 
use; mMRC, modified Medical Research Council; RV, residual 
volume; TLC, total lung capacity.




committee will confirm eligibility and suitability of patients se-
lected for participation in the ELEVATE trial. The ERC and RRC 
serve as a virtual multidisciplinary team, to assure consistency in 
patient selection. A complete treatment includes 2 procedures, ap-
proximately 2 months apart, providing bilateral treatment to the 
most destroyed lobe of each lung. A detailed description of the 
state-of-the-art treatment has recently been published by Slebos et 
al. [10].
Primary and Secondary Endpoints
The objective of the study is to prospectively confirm the safety 
and effectiveness profile of coil treatment in consideration of the 
findings of previous randomized controlled trials [20, 21]. The co-
primary endpoints are the percent change in FEV1 and change in 
the St. George’s Respiratory Questionnaire (SGRQ) from baseline 
to 6 months. The secondary endpoints are determination of re-
sponder rates in clinical endpoints and mean change in physiolog-
ic endpoints. Responder rate at 6 months is defined as percent of 
patients that achieve 2 or more of the following minimum clinical 
important differences; a change from baseline in the 6-min walk-
ing test (6MWT) ≥26 m [24], SGRQ ≤–4 points [25], FEV1 ≥10% 
[26], or RV ≤–350 mL [27]. A complete list of endpoints is shown 
in Table 3.
Assessment visits are displayed in Table 4 for both the treat-
ment group and the control group.
Statistical Analysis
All effectiveness parameters will be analyzed on the ITT popu-
lation through the 6-month visit, with missing data imputed using 
Markov chain Monte Carlo multiple imputation. Comparisons 
will be considered significant at a two-sided α level of 0.05. Com-
parisons between treatment groups for the co-primary effective-
ness endpoints will be conducted using analysis of covariance with 
factors of treatment, site, and emphysema heterogeneity as well as 
a covariate of corresponding baseline values. Mean differences be-
tween treatments and corresponding two-sided 95% confidence 
intervals (CIs) will be calculated.
For continuous secondary and other effectiveness endpoints, 
treatment comparisons will be conducted using the same methods 
as for the co-primary endpoints. For responder endpoints, treat-
ment groups will be compared using logistic regression with fac-
tors of treatment, site, and heterogeneity as well as a covariate of 
corresponding baseline values. Odds ratios (ORs) with corre-
sponding 95% CIs will be computed as well as response rates for 
each treatment group. In addition, the results of the EuroQol-5 
dimension QoL questionnaire (EQ-5D) will be summarized by 
shift tables for each dimension.
For continuous effectiveness endpoints with significant devia-
tions from normality, treatment groups will be compared using a 
nonparametric rank-transformed analysis of covariance as the pri-
mary analysis, and median differences will be computed.
Subgroup analysis for primary and secondary effectiveness mea-
sures will include a comparison of results by disease distribution (bi-
lateral heterogeneous, bilateral homogeneous, and mixed) as defined 
per QCT (heterogeneous defined by ≥15% ipsilateral difference in 
%LAA at –950 HU) and RV at baseline of 200–225 or > 225%.
Sample size was selected based on RENEW post hoc analyses 
to provide ≥85% power to detect a difference of 10% in mean per-
cent change in FEV1 and –7 points in mean change in SGRQ be-
tween treatment and control groups simultaneously as co-primary 
Table 2. The ELEVATE trial exclusion criteria
– Meets any of the contraindications listed in the instructions 
for use
– Primary diagnosis of asthma
– Two or more exacerbations of chronic obstructive pulmonary 
disease (COPD) in the prior year, or 1 or more COPD exacer-
bations in the prior 3 months with indication for hospitaliza-
tion assessment according to GOLD 2017 recommendations
– Predominant small-airway disease defined as significant 
bronchiectasis with sputum production (>2 tablespoons dai-
ly) or significant bronchial wall thickening per high-resolu-
tion CT
– Percent low attenuation area <20% in the most damaged lobe 
of either lung
– CT imaging consistent with active pulmonary infection, sig-
nificant interstitial disease, or pleural disease (predominant 
bulla >8 cm or 1/3 hemithorax), or severe bullous or predom-
inant paraseptal emphysema pattern
– Lung pathology of nodule not proven stable or benign
– Radiographic confirmation of atelectasis or other scarring/
fibrosis in areas of intended coil implantation
– Use of >10 mg/day prednisolone or equivalent dosage of a 
different corticosteroid
– Severe pulmonary hypertension (right ventricular systolic 
pressure >50 mm Hg or other signs of pulmonary hyperten-
sion with right ventricular dysfunction)
– Severe hypercapnia (PaCO2 >55 mm Hg on room air) and/or 
severe hypoxemia (PaO2 <45 mm Hg on room air, high alti-
tude criterion: PaO2 <30 mm Hg)
– Previous lung volume reduction (LVR) surgery, lung trans-
plantation, lobectomy, LVR devices, or other device to treat 
COPD in either lung
– Diagnosed with α1-antitrypsin deficiency
– Diffusing capacity of the lung for CO <20%
– Significant, recent, or unstable cardiac disease defined as 
severe heart failure (left ventricular ejection fraction <45% 
despite optimal medical management), unstable cardiac ar-
rhythmia, or coronary artery disease (angina on activity), or 
ischemic event in the past 6 months
– Body mass index >30
GOLD, Global Strategy for the Diagnosis, Management, and 
Prevention of COPD, Global Initiative for Chronic Obstructive 
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Fig. 3. Eligibility workflow. Patient must have T×2 visit ≤45 days from baseline visit. Study goal is 16 days (ERC 
agreement) and 30 days (ERC agreement) for randomization to accommodate site scheduling.




Table 3. Study endpoints
Co-primary effectiveness endpoint Secondary endpoints Other effectiveness endpoints
Percent change in FEV1 
from baseline to 6 months
Responder rate at 6 months defined as percent of 
subjects that achieve 2 or more of the following  
MCIDs
Changes in other pulmonary function 
measures (RV, RV/TLC, FEV1, FEV1/
FVC)
Change in SGRQ from baseline to 6 months Change from baseline in:
6MWT ≥26 m [13]
SGRQ ≤–4 points [14]
FEV1 ≥10% [15]
RV ≤–350 mL [16]
– Change in mean expiratory target lobar volume 
measured by HRCT (lobar RV) from baseline to  
6 months
– Change in VC as measured by plethysmography 
from baseline to 6 months
– Change in exercise capacity 
(6MWT)
– Mean change at 6 months for CAT 
and EQ5D
– Individual MCID responders at 6 
months for 6MWT, SGRQ, and FEV1 
as defined above
– Responder rate at 6 months defined 
as percent of subjects that achieve 
FEV1 ≥12%
– Responder rate at 6 months defined 
as percent of subjects that achieve 
SGRQ ≤–8 points
6MWT, 6-min walking test; CAT, COPD assessment test; EQ-5D, EuroQol-5 dimensions quality of life questionnaire; FEV1, forced 
expiratory volume in 1 s; HRCT, high-resolution CT; lobar RV, mean expiratory lobar volume of the treated lobes calculated via quan-
titative CT analysis of the expiratory HRCT scans; MCID, minimum clinical important difference; RV, residual volume; SGRQ, St. 
George’s respiratory questionnaire; TLC, total lung capacity; VC, vital capacity.
Table 4. Patient schedule
Baseline visit
Randomization (2:1)
                                      Treatment group                                               Control group
First coil treatment (<45 days from baseline)
Phone call visit 1 (1 week after first coil treatment) Phone call visit 1 (1 week after randomization)
1 month after first coil treatment
Second coil treatment (2 months after first procedure)
Phone call visit 2 (1 week after second coil treatment) Phone call visit 2 (2 months after randomization)
1 month after second coil treatment
Phone call visit 3 (4.5 months after first coil treatment) Phone call visit 3 (4.5 months after randomization)
6-month follow-up 6 months after baseline visit
12-month follow-up First coil treatment (<30 days after 6-month visit)
24-month follow-up Phone call visit 4 (1 week after first coil treatment)
1 month after first coil treatment
Second coil treatment (2 months after first procedure)
Phone call visit 5 (1 week after second coil treatment)
1 month after second coil treatment








endpoints (e.g., 90% power for percent change in FEV1 and > 95% 
power for change in SGRQ such that co-primary power ≥90% × 
95% = 85%). One hundred and forty subjects in the treatment 
group and 70 subjects in the control group are required, assuming 
a SD of 20 and 12 for percent change in FEV1 and change in SGRQ, 
respectively, using a 2-sample t test and a two-sided α level of 5%, 
allowing for a dropout rate of up to 9%. A sample size modification 
will be considered after 50% of patients have completed the 
6-month follow-up visit by evaluating the co-primary effectiveness 
endpoints using the promising zone sample size re-estimation 
method of Mehta and Pocock [28].
Safety
An independent data safety monitoring board (DSMB) will 
oversee the conduct of the study. The DSMB will review and eval-
uate serious adverse events on an “as needed” basis as requested by 
the sponsor and all reported adverse events at minimum on a quar-
terly basis. The committee may recommend a temporary hold or 
discontinuation of the study in the event of the occurrence of seri-
ous or unexpected adverse events that are determined by the 
DSMB to pose a significant safety concern.
Discussion
Coil placement has demonstrated effectiveness and 
an acceptable safety profile in multiple clinical trials 
[20, 29–34]. All randomized controlled trials reached 
their primary endpoints with statistical significance. A 
recent 2-year follow-up of the REVOLENS (Réduction 
volumique endobronchique par spirales) trial showed 
sustained response in QoL and no unexpected safety 
events [35]. However, improvements in exercise capac-
ity (6MWT) and lung function (FEV1) in the RENEW 
trial were considered to be rather modest. The initial 
RENEW analysis has shown greater treatment effects in 
the subgroup with a baseline RV > 225% . Further anal-
yses were done to explore potential predictors of better 
clinical outcomes [21]. These post hoc analyses identi-
fied a patient subgroup that achieved statistically clini-
cally meaningful improvements in pulmonary function 
and volume reduction outcomes 12 months after coil 
treatment [21]. These patients had higher emphysema 
scores (> 20% LAA), higher baseline RV (> 200%), and 
absence of significant airway disease. In fact, a recent 
meta-analysis including almost 2,800 patients with em-
physema who underwent either a surgical or endoscop-
ic lung volume reduction procedure confirmed a high 
correlation between the degree of volume reduction 
and relevant outcomes of obstructive pulmonary dis-
ease (COPD), such as FEV1, 6MWT, and QoL (SGRQ) 
[4]. The ELEVATE trial thus has been designed with 
patient inclusion and exclusion criteria that take the pa-
tient selection findings from the RENEW post hoc anal-
ysis into account. In addition, both an RRC and an ERC 
are used to identify patients with severe emphysema 
that would most likely benefit from coil therapy. The 
inevitable limitation of this study, however, is the open-
label design. Given that coils are visible on X-ray (which 
is required during the postprocedural follow-up) and 
patients frequently experience mild hemoptysis follow-
ing the procedure, unblinding physicians and/or pa-
tients was deemed not practicable for this particular 
technology. 
Finally, although patient selection criteria remain cru-
cial for treatment success, different safety profiles of the 
available therapies must also be taken into consideration. 
While the most common adverse event for valve therapy 
is pneumothorax, with a rate as high as 30% [16, 17], the 
most common side effects of coil therapy are pneumonia 
(18% in the RENEW trial) and COPD exacerbations (26% 
in the RENEW trial), whereas the pneumothorax rates 
following coil insertion are substantially lower with an 
incidence of 6–10% [10, 20, 29]. In comparison to endo-
scopic lung volume reduction techniques, patients un-
dergoing lung volume reduction surgery appear to have 
substantially higher complication rates overall. In an 
analysis of the NETT results, Criner and Sternberg [36] 
reported a 60% incidence of at least 1 complication with-
in 30 days of surgery, 21% of patients required at least 1 
reintubation, and 11% were readmitted to the intensive 
care unit. Furthermore, close to 40% of patients had a 
prolonged air leak of > 7 days. 
Conclusions
Patients with severe emphysema have limited treat-
ment options. Endobronchial coils may provide a mini-
mally invasive alternative for these patients. Endobron-
chial coils have demonstrated improved exercise capacity 
and QoL with a sustained benefit over 2 years for some 
patients [20, 35]. The ELEVATE trial aims to establish 
more sophisticated patient selection criteria that will 
identify those patients that are most likely to benefit from 
endobronchial coils. The objective of the study is to pro-
spectively confirm the safety and effectiveness profile of 
the coil system for the treatment of severe emphysema in 
consideration of the findings of previous randomized 
controlled trials. Secondary objectives are the determina-
tion of responder rates to clinical endpoints and mean 
change in physiologic endpoints.





The study required a completed patient informed consent form 
from all participating patients, which was reviewed and approved 
by the ethics committees of all participating sites. The study was 
conducted in accordance with Good Clinical Practice guidelines, 
and all applicable country, state, and local regulations.
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